TGR5 in the cholangiociliopathies

Digestive Diseases

Volumn 33, Issue 3, 2015, Pages 420-425

  Masyuk, Tatyana V ^a   Masyuk, Anatoliy I ^a   Larusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cholangiociliopathies; Cholangiocytes; Cilia; Hepatic cysts; Polycystic liver disease

Indexed keywords

CYCLIC AMP; FIBROCYSTIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 5; POLYCYSTIN 1; POLYCYSTIN 2; UNCLASSIFIED DRUG; GPBAR1 PROTEIN, HUMAN;

APICAL MEMBRANE; AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE; BILE DUCT CARCINOMA; CELL PROLIFERATION; CELLS BY BODY ANATOMY; CHOLANGIOCYTE; CILIATED EPITHELIUM CELL; CONFERENCE PAPER; CYTOKINE PRODUCTION; ENZYME ACTIVATION; HUMAN; INTRACELLULAR SIGNALING; KIDNEY POLYCYSTIC DISEASE; KUPFFER CELL; LIVER CYST; LIVER POLYCYSTIC DISEASE; NONHUMAN; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; BILE DUCT; BILE DUCT TUMOR; CYST; CYTOLOGY; EPITHELIUM CELL; EUKARYOTIC FLAGELLUM; GENETICS; LIVER DISEASE; METABOLISM; SCLEROSING CHOLANGITIS; SIGNAL TRANSDUCTION;

BILE DUCT NEOPLASMS; BILE DUCTS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CILIA; CYCLIC AMP; CYSTS; EPITHELIAL CELLS; HUMANS; LIVER DISEASES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84930579735     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000371696     Document Type: Conference Paper

References (36)

1. Schaap FG, Trauner M, Jansen PL: Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
2. Pols TW: TGR5 in inflammation and cardiovascular disease. Biochem Soc Trans 2014; 42: 244-249.
3. Duboc H, Tache Y, Hofmann AF: The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014; 46: 302-312.
4. Keitel V, Haussinger D: TGR5 in cholangiocytes. Curr Opin Gastroenterol 2013; 29: 299-304.
5. Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D: Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372: 78-84.
6. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D: The membranebound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50: 861-870.
7. Masyuk AI, Huang BQ, Radtke BN, Gajdos GB, Splinter PL, Masyuk TV, Gradilone SA, LaRusso NF: Ciliary subcellular localization of TGR5 determines the cholangiocyte functional response to bile acid signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304:G1013-G1024.
8. Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M: Involvement of membrane-type bile acid receptor M-BAR/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2007; 354: 154-159.
9. Zhong M: TGR5 as a therapeutic target for treating obesity. Curr Top Med Chem 2010; 10: 386-396.
10. Yoneno K, Hisamatsu T, Shimamura K, Kamada N, Ichikawa R, Kitazume MT, Mori M, Uo M, Namikawa Y, Matsuoka K, Sato T, Koganei K, Sugita A, Kanai T, Hibi T: TGR5 signalling inhibits the production of pro-inflammatory cytokines by in vitro differentiated inflammatory and intestinal macrophages in Crohn's disease. Immunology 2013; 139: 19-29.
11. Tiwari A, Maiti P: TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders. Drug Discov Today 2009; 14: 523-530.
12. Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K: TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-177.
13. Stepanov V, Stankov K, Mikov M: The bile acid membrane receptor TGR5: A novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 2013; 33: 213-223.
14. Keitel V, Reich M, Haussinger D: TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis? Clin Rev Allergy Immunol 2014, Epub ahead of print.
15. Masyuk AI, Masyuk TV, LaRusso NF: Cholangiocyte primary cilia in liver health and disease. Dev Dyn 2008; 237: 2007-2012.
16. Masyuk T, Masyuk A, LaRusso N: Cholangiociliopathies: genetics, molecular mechanisms and potential therapies. Curr Opin Gastroenterol 2009; 25: 265-271.
17. Torres VE, Harris PC: Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am So Nephrol 2014; 25: 18-32.
18. Chandok N: Polycystic liver disease: A clinical review. Ann Hepatol 2012; 11: 819-826.
19. Cnossen WR, Drenth JP: Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management. Orphanet J Rare Dis 2014; 9: 69.
20. Harris PC, Torres VE: Polycystic kidney disease. Annu Rev Med 2009; 60: 321-337.
21. Masyuk T, LaRusso N: Polycystic liver disease: new insights into disease pathogenesis. Hepatology 2006; 43: 906-908.
22. Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, LaRusso NF: HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res 2013; 73: 2259-22570.
23. Strazzabosco M, Somlo S: Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology 2011; 140: 1855-1859, 1859. e1.
24. Wills ES, Roepman R, Drenth JP: Polycystic liver disease: ductal plate malformation and the primary cilium. Trends Mol Med 2014; 20: 261-270.
25. Masyuk AI, Masyuk TV, Splinter PL, Huang BQ, Stroope AJ, LaRusso NF: Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology 2006; 131: 911-920.
26. Banales JM, Masyuk TV, Bogert PS, Huang BQ, Gradilone SA, Lee SO, Stroope AJ, Masyuk AI, Medina JF, LaRusso NF: Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease. Am J Pathol 2008; 173: 1637-1646.
27. Banales JM, Masyuk TV, Gradilone SA, Masyuk AI, Medina JF, LaRusso NF: The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD). Hepatology 2009; 49: 160-174.
28. Masyuk TV, Huang BQ, Ward CJ, Masyuk AI, Yuan D, Splinter PL, Punyashthiti R, Ritman EL, Torres VE, Harris PC, LaRusso NF: Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. Gastroenterology 2003; 125: 1303-1310.
29. Masyuk TV, Huang BQ, Masyuk AI, Ritman EL, Torres VE, Wang X, Harris PC, Larusso NF: Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease. Am J Pathol 2004; 165: 1719-1730.
30. Masyuk AI, Gradilone SA, Banales JM, Huang BQ, Masyuk TV, Lee SO, Splinter PL, Stroope AJ, Larusso NF: Cholangiocyte primary cilia are chemosensory organelles that detect biliary nucleotides via P2Y12 purinergic receptors. Am J Physiol Gastrointest Liver Physiol 2008; 295:G725-G734.
31. Masyuk TV, Lee SO, Radtke BN, Stroope AJ, Huang B, Banales JM, Masyuk AI, Splinter PL, Gradilone SA, Gajdos GB, LaRusso NF: Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression. Am J Pathol 2014; 184: 110-121.
32. Masyuk TV, Masyuk AI, Torres VE, Harris PC, LaRusso NF: Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine ,5 -cyclic monophosphate. Gastroenterology 2007; 132: 1104-1116.
33. Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF: Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013; 58: 409-421.
34. Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, LaRusso NF, Torres VE: Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-3539.
35. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR 3rd, Rossetti S, Harris PC, LaRusso NF, Torres VE: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010; 21: 1052-1061.
36. Keitel V, Haussinger D: Perspective: TGR5 (Gpbar-1) in liver physiology and disease. Clin Res Hepatol Gastroenterol 2012; 36: 412-419.